Empagliflozin for people with Brugada syndrome
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests whether the medicine empagliflozin, usually used for diabetes, can help people with Brugada syndrome, a rare heart condition that affects heart rhythm. If you have Brugada syndrome, this treatment might help prevent dangerous heart rhythms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Brugada syndrome and be at least 18 years old.
- Your ECG must show a specific pattern called type 1, but not just from a fever or medication.
- Your heart must be structurally normal with clear arteries.
- You cannot have used an SGLT2 inhibitor (a type of diabetes medicine) in the past 12 weeks.
- You cannot have certain heart or kidney conditions, or a history of ketoacidosis.
- You must be willing to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.
This trial tests if a diabetes medicine called empagliflozin can help people with Fontan circulatory failure feel better and do more of their daily activities.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This trial tests if a diabetes drug called empagliflozin can help the heart's left atrium work better in people who have had a stroke with no known cause. You may join if you are getting a heart monitor device implanted to look for hidden irregular heartbeats.
Hear when a new Brugada Syndrome (BrS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.